Mesoblast Limited ( ($AU:MSB) ) has provided an update. An independent study presented at the American Society of Hematology Annual Meeting ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy ...

Patients with <7/8 transplants had a 1-year survival of 85.6% versus 78.6% for those who received better-matched donor cells.

Treatment with Zervyteg (MaaT013) generated encouraging results and demonstrated an acceptable safety profile in patients with acute graft-vs-host disease that affects the gastrointestinal tract and ...

A specific graft-versus-host disease prophylaxis regimen may expand allogeneic hematopoietic stem cell transplant access to ...

Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...

A "hybrid" immune system approach may prevent or cure Type 1 diabetes (T1D) by combining blood stem cell and islet cell transplants. The method uses a nonmyeloablative conditioning regimen to prevent ...

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...